AR012927A1 - Una composicion farmaceutica, una forma de dosificacion farmaceutica, el uso de dicha composicion para la fabricacion de un medicamento y una forma depresentacion farmaceutica adecuada para la venta comercial - Google Patents

Una composicion farmaceutica, una forma de dosificacion farmaceutica, el uso de dicha composicion para la fabricacion de un medicamento y una forma depresentacion farmaceutica adecuada para la venta comercial

Info

Publication number
AR012927A1
AR012927A1 ARP980102651A ARP980102651A AR012927A1 AR 012927 A1 AR012927 A1 AR 012927A1 AR P980102651 A ARP980102651 A AR P980102651A AR P980102651 A ARP980102651 A AR P980102651A AR 012927 A1 AR012927 A1 AR 012927A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical
composition
manufacture
commercial sale
dosage form
Prior art date
Application number
ARP980102651A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR012927A1 publication Critical patent/AR012927A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Una novedosa composicion farmacéutica que consiste en un compuesto farmacéutico no más que escasamente soluble, una ciclodextrina, un ácidosoluble en agua fisiologicamente tolerable y un polímero orgánico soluble en agua fisiologicamentetolerable. Además se describe una composicionfarmacéutica, una forma de dosificacion farmacéutica, el uso de dicha composicion para la fabricacion de un medicamento y una forma de presentacionfarmacéutica adecuada para la venta comercial.
ARP980102651A 1997-06-05 1998-06-04 Una composicion farmaceutica, una forma de dosificacion farmaceutica, el uso de dicha composicion para la fabricacion de un medicamento y una forma depresentacion farmaceutica adecuada para la venta comercial AR012927A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9711643.8A GB9711643D0 (en) 1997-06-05 1997-06-05 Glass thermoplastic systems

Publications (1)

Publication Number Publication Date
AR012927A1 true AR012927A1 (es) 2000-11-22

Family

ID=10813624

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102651A AR012927A1 (es) 1997-06-05 1998-06-04 Una composicion farmaceutica, una forma de dosificacion farmaceutica, el uso de dicha composicion para la fabricacion de un medicamento y una forma depresentacion farmaceutica adecuada para la venta comercial

Country Status (19)

Country Link
US (1) US20020150616A1 (es)
EP (1) EP0998304B1 (es)
JP (1) JP2002511073A (es)
KR (1) KR20010005852A (es)
CN (1) CN1258220A (es)
AR (1) AR012927A1 (es)
AT (1) ATE247489T1 (es)
AU (1) AU8108198A (es)
CA (1) CA2292506A1 (es)
DE (1) DE69817363T2 (es)
DK (1) DK0998304T3 (es)
ES (1) ES2206949T3 (es)
GB (1) GB9711643D0 (es)
HU (1) HUP0004924A2 (es)
IL (1) IL133293A0 (es)
NO (1) NO995925L (es)
PT (1) PT998304E (es)
WO (1) WO1998055148A1 (es)
ZA (1) ZA984849B (es)

Families Citing this family (373)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ330596A (en) * 1998-06-05 2001-02-23 Dec Res Intravaginal devices allowing for increased uptake of active ingredients
US7588793B1 (en) 1998-06-05 2009-09-15 Cadbury Adams Usa, Llc Enhanced flavoring compositions containing N-ethyl-p-menthane-3-carboxamide and method of making and using same
WO2000038686A1 (en) 1998-12-24 2000-07-06 Janssen Pharmaceutica N.V. Controlled release galantamine composition
ES2306646T3 (es) * 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
US6497905B1 (en) 1999-03-24 2002-12-24 R.P. Scherer Technologies, Inc. Aqueous solubility pharmaceutical formulations
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
ATE248165T1 (de) * 1999-07-01 2003-09-15 Italfarmaco Spa Komplexe von paroxetin mit cyclodextrin oder cyclodextrin derivaten
AU5975700A (en) * 1999-07-02 2001-01-22 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
US6835717B2 (en) 2000-03-08 2004-12-28 The Johns Hopkins University School Of Medicine β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
SI1278549T1 (sl) 2000-05-02 2009-04-30 Theravance Inc Sestavek, ki vsebuje ciklodekstrin in glikopeptidni antibiotik
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
DK1526134T3 (da) 2000-05-26 2008-11-17 Pfizer Triazolyltropanderivater som CCR5-modulatorer
US6667314B2 (en) 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
CN1322850C (zh) * 2000-06-02 2007-06-27 沈阳药科大学 盐酸尼卡地平粉针剂及其制备方法
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
GB0015239D0 (en) * 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
US6420557B1 (en) 2000-07-28 2002-07-16 Pfizer Inc. Crystalline therapeutic agent
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
AU2002245181B2 (en) 2000-12-21 2006-06-29 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
NZ529403A (en) 2001-04-10 2005-06-24 Pfizer Pyrazole derivatives for treating HIV
GB0116453D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Method
FR2827516B1 (fr) * 2001-07-19 2003-09-19 Servier Lab Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
CN100384865C (zh) * 2001-11-02 2008-04-30 嵌入治疗公司 用于rna干扰的治疗用途的方法及组合物
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
RS70104A (en) 2002-02-11 2007-02-05 Pfizer Limited, Nicotinamide derivatives useful as pde4 inhibitors
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
GB0207104D0 (en) 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
US20050255164A1 (en) * 2002-08-15 2005-11-17 Yunging Liu Solid nano pharmaceutical formulation and preparation method thereof
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221169D0 (en) 2002-09-12 2002-10-23 Univ Bath Crystal
EP1545477A4 (en) * 2002-09-13 2006-11-22 Cydex Inc CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN
US7230025B2 (en) 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
JP2006511606A (ja) 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 下部尿路症状を治療するα−２−δリガンド
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US7993654B2 (en) * 2002-12-23 2011-08-09 Beiersdorf Ag Self-adhesive polymer matrix containing sea algae extract
DE10260872B4 (de) 2002-12-23 2013-09-26 Beiersdorf Ag Verwendung von gelbildendem Polymer, Wasser, Alkohol und Meeresalgenextrakt zur Einstellung von Elastizität und Haftvermögen selbstklebender kosmetischer Polymermatrices
DE10260873A1 (de) 2002-12-23 2004-07-15 Beiersdorf Ag Selbstklebende Polymermatrix mit einem Gehalt an Meeresalgenextrakt und Glycerin
US20060177498A1 (en) * 2003-01-22 2006-08-10 Ramaswami Bharatrajan Solid pharmaceutical composition comprising ramipril
WO2004082590A2 (en) * 2003-02-17 2004-09-30 Sun Pharmaceutical Industries Limited A low dose corticosteroid composition
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
EP1608343B1 (en) 2003-03-28 2016-04-27 Ares Trading S.A. Cladribine formulations for improved oral and transmucosal delivery
DK2272503T3 (da) * 2003-03-28 2013-05-21 Ares Trading Sa Orale formuleringer af cladribin
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
EP1663166A2 (en) * 2003-09-02 2006-06-07 Imran Ahmed Sustained release dosage forms of ziprasidone
PL1664036T3 (pl) 2003-09-03 2012-04-30 Pfizer Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
US7875630B2 (en) 2003-09-03 2011-01-25 Glaxo Group Limited Process salts compositions and use
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
US6960300B2 (en) * 2003-09-08 2005-11-01 Sami Labs Limited Process for preparing water soluble diterpenes and their applications
AU2004271800A1 (en) 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
AU2004278158B2 (en) 2003-10-03 2009-08-13 Pfizer Inc. Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US8591973B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
US8389031B2 (en) 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Coated delivery system for active components as part of an edible composition
US8591968B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Edible composition including a delivery system for active components
US20050112236A1 (en) 2003-11-21 2005-05-26 Navroz Boghani Delivery system for active components as part of an edible composition having preselected tensile strength
US8591972B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for coated active components as part of an edible composition
US8389032B2 (en) 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US8597703B2 (en) 2005-05-23 2013-12-03 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
CA2546347A1 (en) 2003-11-21 2005-06-09 Combinatorx, Incorporated Methods and reagents for the treatment of inflammatory disorders
US8591974B2 (en) 2003-11-21 2013-11-26 Kraft Foods Global Brands Llc Delivery system for two or more active components as part of an edible composition
US9271904B2 (en) 2003-11-21 2016-03-01 Intercontinental Great Brands Llc Controlled release oral delivery systems
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
JP4036343B2 (ja) 2004-01-22 2008-01-23 ファイザー・インク 疾患の治療のためのスルフォンアミド誘導体
EA011167B1 (ru) 2004-01-22 2009-02-27 Пфайзер Инк. Производные сульфонамида для лечения заболеваний
US7629358B2 (en) 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
AU2005223483B2 (en) 2004-03-18 2009-04-23 Zoetis Llc N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
PL1730103T3 (pl) 2004-03-23 2010-10-29 Pfizer Pochodne formamidu użyteczne jako adrenoreceptor
US7538141B2 (en) 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
KR100479367B1 (ko) * 2004-04-13 2005-03-29 (주) 에프디엘 이트라코나졸을 포함하는 경구투여용 항진균제 조성물
BRPI0510453A (pt) 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
WO2005117911A2 (en) * 2004-05-06 2005-12-15 Cydex, Inc. Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
KR100875558B1 (ko) 2004-06-15 2008-12-23 화이자 인코포레이티드 벤즈이미다졸론 카복실산 유도체
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US20050282895A1 (en) * 2004-06-21 2005-12-22 Dosch Michael H Antimicrobial compositions and methods of use thereof
CA2576344C (en) * 2004-08-11 2010-10-05 Cadbury Adams Usa Llc Warming compositions and delivery systems therefor
GEP20104973B (en) 2004-08-12 2010-04-26 Pfizer Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
US20060068058A1 (en) * 2004-09-30 2006-03-30 Cadbury Adams Usa Llc Thermally stable, high tensile strength encapsulation compositions for actives
US7727565B2 (en) 2004-08-25 2010-06-01 Cadbury Adams Usa Llc Liquid-filled chewing gum composition
US7955630B2 (en) 2004-09-30 2011-06-07 Kraft Foods Global Brands Llc Thermally stable, high tensile strength encapsulated actives
PL1786785T3 (pl) 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
CN1325054C (zh) * 2004-09-29 2007-07-11 南京师范大学 盐酸哌唑嗪的环糊精包合物及其制备方法
ATE417830T1 (de) 2004-11-02 2009-01-15 Pfizer Sulfonylbenzimidazolderivate
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
JP4335120B2 (ja) 2004-11-08 2009-09-30 カゴメ株式会社 混合飲料の製造方法
US9198448B2 (en) * 2005-02-07 2015-12-01 Intercontinental Great Brands Llc Stable tooth whitening gum with reactive ingredients
US8703099B2 (en) 2005-02-24 2014-04-22 Dr Pharma Nova, Llc Registry method and control system for DEA schedule II-V medicines
CN101160285A (zh) 2005-03-17 2008-04-09 辉瑞大药厂 适用于治疗疼痛的n-(n-磺酰氨基甲基)环丙烷甲酰胺衍生物
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
ES2525096T3 (es) 2005-04-19 2014-12-17 Kings College London Uso de bip contra la pérdida ósea y osteoporosis
EP1874292A2 (en) * 2005-04-24 2008-01-09 Wyeth Methods for modulating bladder function
AU2006242920A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
US7851006B2 (en) 2005-05-23 2010-12-14 Cadbury Adams Usa Llc Taste potentiator compositions and beverages containing same
AR053295A1 (es) 2005-05-23 2007-04-25 Cadbury Adams Usa Llc Composiciones que potencian el sabor y golosinas comestibles y productos de goma de mascar que los contienen
US7851005B2 (en) 2005-05-23 2010-12-14 Cadbury Adams Usa Llc Taste potentiator compositions and beverages containing same
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
US20080146643A1 (en) * 2005-06-15 2008-06-19 Pfizer Limited Combination
AU2006257647A1 (en) 2005-06-15 2006-12-21 Pfizer Limited Substituted arylpyrazoles for use against parasites
US20080176865A1 (en) * 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20070221236A1 (en) * 2005-10-05 2007-09-27 Cadbury Adams Usa Llc. Cooling compositions including menthyl esters
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
EP1959966B1 (en) * 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
US8846007B2 (en) * 2005-12-23 2014-09-30 Intercontinental Great Brands Llc Compositions providing a heating sensation for oral or dermal delivery
CN101346073B (zh) * 2005-12-23 2013-02-13 卡夫食品环球品牌有限责任公司 提供基本上类似于由薄荷醇提供的感觉的组合物
GB0600406D0 (en) 2006-01-10 2006-02-15 Univ Bath Crystal
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
WO2007112065A2 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
PE20080126A1 (es) * 2006-03-24 2008-04-07 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines
MX2008012105A (es) * 2006-03-24 2008-10-03 Wyeth Corp Metodos para modular la funcion de la vejiga.
JP2009531434A (ja) * 2006-03-24 2009-09-03 ワイス 痛みの治療
CN101410112A (zh) * 2006-03-24 2009-04-15 惠氏公司 治疗抑郁症的新治疗组合
KR100917809B1 (ko) 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
EP2040744B1 (en) 2006-07-25 2016-03-09 The Secretary of State for Defence Live vaccine strains of francisella
US20080207731A1 (en) 2006-08-23 2008-08-28 Intellect Neurosciences, Inc. 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2068853A2 (en) 2006-09-15 2009-06-17 Stevia APS Treatment of insulin resistance or diseases associated with insulin resistance with bicyclo[3.2.1]octans such as steviol and isosteviol
CA2657550C (en) 2006-09-21 2011-11-01 Raqualia Pharma Inc. Benzimidazole derivatives as selective acid pump inhibitors
BRPI0719250A2 (pt) 2006-10-12 2015-06-16 Wyeth Corp Métodos e composições com opalescência reduzida.
KR101181194B1 (ko) 2006-10-18 2012-09-18 화이자 프로덕츠 인코포레이티드 바이아릴 에터 우레아 화합물
WO2008050199A2 (en) 2006-10-23 2008-05-02 Pfizer Japan Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
EP2395077A1 (en) 2006-11-03 2011-12-14 Wyeth LLC Glycolysis-inhibiting substances in cell culture
ES2312308T3 (es) 2006-11-17 2013-03-26 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
EP2101735A2 (en) 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
AU2007329373B2 (en) * 2006-12-04 2013-06-20 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
JP4523073B2 (ja) 2007-02-06 2010-08-11 ファイザー・インク 癌を治療するためのＨＳＰ−９０阻害剤としての２−アミノ−５，７−ジヒドロ−６Ｈ−ピロロ［３，４−ｄ］ピリミジン誘導体
AU2008223133A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
WO2008142550A2 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic derivatives
TWI364290B (en) 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
KR101225233B1 (ko) 2007-09-05 2013-01-22 화이자 리미티드 Ｎ4-(2,2-다이플루오로-4ｈ-벤조〔1,4〕옥사진-3-온)-6-일〕-5-플루오로-ｎ2-〔3-(메틸아미노카보닐메틸렌옥시)페닐〕2,4-피리미딘다이아민의 지나포에이트 염
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
US20090130251A1 (en) * 2007-11-20 2009-05-21 Cadbury Adams Usa Llc Dual coated confectionery product
GB2458473A (en) 2008-03-17 2009-09-23 Imuthes Ltd 3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
US20090275622A1 (en) * 2008-04-30 2009-11-05 Prasoona Linga Nizatidine formulations
EP2313111B1 (en) 2008-08-01 2013-09-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
EP2163253B1 (en) 2008-09-15 2013-07-17 ULLRICH, Oliver Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
ES2549005T3 (es) 2008-11-21 2015-10-22 Raqualia Pharma Inc Nuevo derivado de pirazol-3-carboxamida que tiene actividad antagonista del receptor 5-HT2B
KR101128450B1 (ko) * 2008-12-11 2012-03-28 (주)바이오제닉스 안정화제로서 β-싸이클로덱스트린 유도체를 포함하는 조성물
MX2011006516A (es) 2008-12-17 2011-08-04 Genentech Inc Terapia de combinacion de virus de hepatitis c.
PE20142099A1 (es) 2009-01-12 2014-12-13 Icagen Inc Derivados de sulfonamida
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
NZ594011A (en) 2009-01-14 2013-12-20 Novacta Biosystems Ltd Deoxyactagardine derivatives
JP5731407B2 (ja) 2009-02-04 2015-06-10 ノヴァクタ バイオシステムズ リミティッド アクタガルジン誘導体
US8828937B2 (en) 2009-03-12 2014-09-09 Haase Investments Ug Bone morphogenetic protein 2 (BMP2) variants with reduced BMP antagonist sensitivity
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US20100291201A1 (en) * 2009-05-14 2010-11-18 Cerovene, Inc. Coated pharmaceutical capsule dosage form
WO2010136940A1 (en) 2009-05-29 2010-12-02 Pfizer Limited Novel glucocorticoid receptor agonists
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
PL2467380T3 (pl) 2009-08-18 2017-09-29 Ventirx Pharmaceuticals, Inc. Podstawione benzoazepiny jako modulatory receptora typu Toll
WO2011022508A2 (en) 2009-08-18 2011-02-24 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
PT2516434E (pt) 2009-12-23 2015-10-05 Takeda Pharmaceutical Pirrolidinonas heteroaromáticas fundidas como inibidores de syk
WO2011083387A1 (en) 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
JP5852966B2 (ja) 2010-02-02 2016-02-03 ノヴァクタ バイオシステムズ リミティッド ランチビオティックの塩
JP2013520489A (ja) 2010-02-25 2013-06-06 ファイザー・リミテッド ペプチド類似体
EP2566858A2 (en) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
WO2011154871A1 (en) 2010-06-10 2011-12-15 Pfizer Limited Hepatitis c virus inhibitors
US9096558B2 (en) 2010-07-09 2015-08-04 Pfizer Limited N-sulfonylbenzamide compounds
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
ES2533065T3 (es) 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
JP2013531030A (ja) 2010-07-12 2013-08-01 ファイザー・リミテッド 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド
CA2801032A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
US8772343B2 (en) 2010-07-12 2014-07-08 Pfizer Limited Chemical compounds
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013508D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013507D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013509D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
NZ607000A (en) 2010-08-24 2015-02-27 Imp Innovations Ltd Glycodendrimers of polypropyletherimine
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
JP5931933B2 (ja) 2011-02-25 2016-06-08 武田薬品工業株式会社 Ｎ−置換オキサジノプテリジンおよびオキサジノプテリジノン
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
CN102139115B (zh) * 2011-03-30 2012-12-05 天津红日药业股份有限公司 阿托伐他汀的环糊精包合物及其口服固体制剂的制备方法
CN103534257A (zh) 2011-04-05 2014-01-22 辉瑞有限公司 作为原肌球蛋白相关激酶抑制剂的吡咯并[2,3-d]嘧啶衍生物
JP5608873B2 (ja) 2011-05-18 2014-10-15 ラクオリア創薬株式会社 ４−｛［４−（｛［４−（２，２，２−トリフルオロエトキシ）−１，２−ベンズイソオキサゾール−３−イル］オキシ｝メチル）ピペリジン−１−イル］メチル｝−テトラヒドロ−２ｈ−ピラン−４−カルボン酸の多形形態
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
US9056873B2 (en) 2011-06-22 2015-06-16 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
WO2013008123A1 (en) 2011-07-13 2013-01-17 Pfizer Limited Enkephalin analogues
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
KR20140041906A (ko) 2011-08-02 2014-04-04 화이자 인코포레이티드 암의 치료에 사용하기 위한 크리조티닙
WO2013017136A1 (en) 2011-08-02 2013-02-07 Pensieve Biosciences Cyprus Limited Treatment of cognitive impairment
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
JP5363636B2 (ja) 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
PE20141682A1 (es) 2011-10-26 2014-11-14 Pfizer Ltd Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
US9273011B2 (en) 2011-10-28 2016-03-01 Inhibitaxin Limited Substituted pyridazines for the treatment of pain
ES2593533T3 (es) 2011-12-15 2016-12-09 Pfizer Limited Derivados de sulfonamida
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
JP6067031B2 (ja) 2012-01-04 2017-01-25 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｎ−アミノスルホニルベンズアミド
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
CA2861439C (en) 2012-02-03 2016-07-12 Pfizer Inc. Benzimidazole and imidazopyridine derivatives as sodium channel modulators
TW201336527A (zh) * 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
LT2822953T (lt) 2012-03-06 2017-04-10 Pfizer Inc. Makrocikliniai dariniai, skirti proliferacinių ligų gydymui
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
UY34893A (es) 2012-07-10 2014-02-28 Takeda Pharmaceutical Derivados de azaindol
EA201590199A1 (ru) * 2012-07-12 2015-05-29 Санофи Противоопухолевая композиция, содержащая соединение 1-(6-{[6-(4-фторфенил)[1,2,4]триазоло[4,3-b]пиридазин-3-ил]сульфанил}-1,3-бензотиазол-2-ил)-3-(2-морфолин-4-илэтил)мочевины
CA2879222A1 (en) * 2012-07-17 2014-01-23 Glaxosmithkline Llc Nicotinamide derivate in the treatment of acute coronary syndrome
EP2909212B1 (en) 2012-09-07 2017-02-22 Takeda Pharmaceutical Company Limited Substituted 1,4-dihydropyrazolo[4,3-b]indoles
US9533989B2 (en) 2012-09-18 2017-01-03 Ziarco Pharma Ltd. Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors
EP2900653A1 (en) 2012-09-28 2015-08-05 Pfizer Inc. Benzamide and heterobenzamide compounds
CA2885253A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
EP2903986A1 (en) 2012-10-04 2015-08-12 Pfizer Limited Tropomyosin-related kinase inhibitors
EP2912036A1 (en) 2012-10-04 2015-09-02 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
GEP201606598B (en) 2012-11-08 2017-01-10 Pfizer Heteroaromatic compounds as dopamine d1 ligands
EP3323821A1 (en) 2012-11-08 2018-05-23 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
CA2890861C (en) 2012-11-21 2021-03-30 Raqualia Pharma Inc. Polymorphic forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
DK2925725T3 (en) 2012-12-03 2017-01-16 Pfizer androgen receptor modulators
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
RU2619944C2 (ru) 2013-02-21 2017-05-22 Пфайзер Инк. Твердые формы селективного ингибитора CDK4/6
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2014181213A1 (en) 2013-05-10 2014-11-13 Pfizer Inc. Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
WO2014207601A1 (en) 2013-06-27 2014-12-31 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
EP3019158A1 (en) 2013-07-08 2016-05-18 AbbVie Inc. Stabilized pharmaceutical dosage forms comprising atrasentan
CN113181110A (zh) * 2013-07-19 2021-07-30 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
CA2934010A1 (en) 2013-12-20 2015-06-25 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2015106014A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
WO2015106012A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
WO2015157509A1 (en) * 2014-04-10 2015-10-15 The Trustees Of The University Of Pennsylvania Compositions and methods for treating opioid receptor associated diseases
EP3131891A1 (en) 2014-04-15 2017-02-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
CA2946471C (en) 2014-04-25 2018-08-07 Pfizer Inc. Fused bicyclic heteroaromatic compounds and their use as dopamine d1 ligands
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
BR112016023740A2 (pt) 2014-04-25 2017-08-15 Pfizer compostos heteroaromáticos e seu uso como ligantes de dopamina d1
EP3137454A1 (en) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
EP3137469B1 (en) 2014-04-28 2019-10-09 Pfizer Inc Heterocyclic compounds and their use as dopamine d1 ligands
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
WO2015173683A1 (en) 2014-05-14 2015-11-19 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
MX371014B (es) 2014-05-15 2020-01-10 Pfizer Forma cristalina de 6-[(4r)-4-metil-1,2-dióxido-1,2,6-tiadiazinan- 2-il]isoquinolin-1-carbonitrilo.
TWI672300B (zh) 2014-05-20 2019-09-21 日商拉夸里亞創藥股份有限公司 苯并異唑衍生物鹽類
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
WO2015181797A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Benzenesulfonamides useful as sodium channel inhibitors
US9802945B2 (en) 2014-06-12 2017-10-31 Pfizer Limited Imidazopyridazine derivatives as modulators of the GABAA receptor activity
PL3157915T3 (pl) 2014-06-17 2019-07-31 Pfizer Inc. Podstawione związki dihydroizochinolinonowe
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
US10017529B2 (en) 2014-09-16 2018-07-10 BioPharma Works LLC Metformin derivatives
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
UY36530A (es) 2015-01-22 2016-08-31 Phytoplant Res S L Métodos para purificar cannabinoides, composiciones y kits de estos
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
CR20170384A (es) 2015-02-24 2017-11-16 Pfizer Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
CA2979527A1 (en) 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease
EP3328849B9 (en) 2015-07-31 2021-01-06 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
US20180193335A1 (en) * 2015-10-12 2018-07-12 Vikash J. BHAGWANDIN Compositions, formulations, packaged pharmaceuticals, and methods of using hedgehog pathway modulators for the sensitization of resistant tumors
CA3007595C (en) 2015-12-10 2020-08-25 Pfizer Limited 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
UY37046A (es) 2015-12-24 2017-07-31 Takeda Pharmaceuticals Co Cocristal, método de produccion del mismo,y medicamento que contiene dicho cocristal
TWI726968B (zh) 2016-01-07 2021-05-11 開曼群島商Ｃｓ醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
ES2837018T3 (es) 2016-01-15 2021-06-29 Pfizer Ligandos del receptor D3 de dopamina de 6,7,8,9-tetrahidro-5H-pirido[2,3-d]azepina
US11753626B2 (en) 2016-03-09 2023-09-12 Beijing Percans Oncology Co., Ltd. Tumor cell suspension cultures and related methods
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
JP2019532021A (ja) 2016-07-29 2019-11-07 ファイザー・インク Ｃ５ａ受容体アンタゴニストとしての環状ペプチド
AU2017311412B2 (en) 2016-08-11 2023-05-18 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
EP3497103B1 (en) 2016-08-15 2021-05-05 Pfizer Inc. Pyridopyrimdinone cdk2/4/6 inhibitors
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
EP3558950B1 (en) 2016-12-20 2023-05-10 Oligomerix, Inc. Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
WO2018134695A1 (en) 2017-01-20 2018-07-26 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
SG11201906427QA (en) 2017-01-23 2019-08-27 Pfizer Heterocyclic spiro compounds as magl inhibitors
DK3600312T3 (da) 2017-03-26 2023-07-31 Takeda Pharmaceuticals Co Piperidinyl- og piperazinylsubstituerede heteroaromatiske carboxamider som modulatorer af gpr6
JOP20180057A1 (ar) 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
SG11201912397RA (en) 2017-06-22 2020-01-30 Curadev Pharma Ltd Small molecule modulators of human sting
TWI830180B (zh) * 2017-06-30 2024-01-21 財團法人工業技術研究院 化合物之液體劑型的醫藥配方
US11773132B2 (en) 2017-08-30 2023-10-03 Beijing Xuanyi Pharmasciences Co., Ltd. Cyclic di-nucleotides as stimulator of interferon genes modulators
MA50245A (fr) 2017-09-11 2020-07-22 Krouzon Pharmaceuticals Inc Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2
TW201920108A (zh) 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
WO2019145552A1 (en) 2018-01-29 2019-08-01 Phytoplant Research S.L Methods of purifying cannabinoids using liquid:liquid chromatography
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
TWI834637B (zh) 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
US10538542B2 (en) 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)
WO2019180072A1 (en) 2018-03-22 2019-09-26 Bayer Pharma Aktiengesellschaft Parenteral pharmaceutical composition comprising neladenoson bialanate
CR20200503A (es) 2018-04-26 2020-12-17 Pfizer Inhibidores de cinasa dependientes de ciclina
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
WO2020016710A1 (en) 2018-07-19 2020-01-23 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
WO2020076728A1 (en) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
EP3886984A1 (en) 2018-11-29 2021-10-06 Pfizer Inc. Pyrazoles as modulators of hemoglobin
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
TWI732431B (zh) 2019-01-23 2021-07-01 美商輝瑞股份有限公司 多形體
AU2020213761C1 (en) 2019-01-31 2023-08-10 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1 Fi-pyrazole compounds having inhibitory activity on CDK2
AR118471A1 (es) 2019-03-22 2021-10-06 Takeda Pharmaceuticals Co Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2
US20220119361A1 (en) 2019-04-29 2022-04-21 Solent Therapeutics, Llc 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
WO2021014415A2 (en) 2019-07-25 2021-01-28 Curadev Pharma Pvt. Ltd. Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
CA3150508A1 (en) 2019-09-16 2021-03-25 Holger Monenschein Azole-fused pyridazin-3(2h)-one derivatives
CA3155569A1 (en) 2019-09-25 2021-04-01 Pfizer Inc. Polyheterocyclic modulators of sting (stimulator of interferon genes)
CN110538094B (zh) * 2019-09-27 2022-01-18 华南理工大学 一种均相亲水和多维稳定的紫檀芪@环糊精包合物及其制备方法
CA3158280A1 (en) 2019-12-06 2021-06-10 Alex Aimetti Ganaxolone for use in treating tuberous sclerosis complex
CN110898015A (zh) * 2019-12-31 2020-03-24 上海汉维生物医药科技有限公司 一种伊曲康唑制剂的制备方法
US20230124361A1 (en) 2020-02-12 2023-04-20 Curadev Pharma Pvt. Ltd. Small molecule sting antagonists
NL2025092B1 (en) * 2020-03-10 2021-10-19 Seranovo Holding B V Solid deep eutectic solvent formulation platform
KR20220163961A (ko) 2020-03-10 2022-12-12 세라노보 홀딩 비.브이. 고체 깊은 공융 용매 제형 플랫폼
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
AR121683A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
EP4121417A4 (en) * 2020-05-01 2023-08-09 University Of Southern California CYCLODEXTRIN-BASED ANTIMICROBIAL THERAPY
MX2022013401A (es) 2020-05-01 2022-11-14 Pfizer Compuestos de azalactama como inhibidores de hpk1.
AU2021266690A1 (en) 2020-05-04 2022-11-10 Takeda Pharmaceutical Company Limited Luminally-acting N-(piperidin-4-yl)benzamide derivatives
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
US20240116937A1 (en) 2020-07-15 2024-04-11 Pfizer Inc. Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
US20230242539A1 (en) 2020-07-15 2023-08-03 Pfizer Inc. Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
GB202011811D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
GB202011812D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
TW202229239A (zh) 2020-09-23 2022-08-01 日商武田藥品工業股份有限公司 作為ｒｉｐｋ２抑制劑之３－（６－胺基吡啶－３－基）苯甲醯胺衍生物
US20220168272A1 (en) * 2021-02-22 2022-06-02 Gholamhossein Yousefi Preparation of soluble form of carvedilol
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
CN113081989B (zh) * 2021-03-29 2022-10-21 海南普利制药股份有限公司 别嘌醇缓释片剂
MX2023011633A (es) 2021-03-31 2023-12-15 Sevenless Therapeutics Ltd Inhibidores de sos1 e inhibidores de ras para su uso en el tratamiento del dolor.
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
EP4320121A2 (en) 2021-04-07 2024-02-14 LifeArc 2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof
JP7511097B1 (ja) 2021-06-26 2024-07-04 アレイ バイオファーマ インコーポレイテッド Ｈｅｒ２変異阻害薬
CA3228653A1 (en) 2021-08-11 2023-02-16 Monali BANERJEE Small molecule urea derivatives as sting antagonists
EP4384267A1 (en) 2021-08-11 2024-06-19 Curadev Pharma Pvt. Ltd. Small molecule sting antagonists
WO2023099072A1 (en) 2021-12-01 2023-06-08 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Compounds
AU2023247317A1 (en) 2022-03-30 2024-10-17 Takeda Pharmaceutical Company Limited N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
AR129012A1 (es) 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
WO2024023727A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Novel acc inhibitors
TW202417456A (zh) 2022-08-10 2024-05-01 日商武田藥品工業股份有限公司 雜環化合物
CN115487080A (zh) * 2022-09-23 2022-12-20 山东博科医用材料有限公司 补骨脂酚微胶囊及其制备方法
WO2024074827A1 (en) 2022-10-05 2024-04-11 Sevenless Therapeutics Limited New treatments for pain
WO2024105363A1 (en) 2022-11-15 2024-05-23 Curadev Pharma Ltd Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1
WO2024157205A1 (en) 2023-01-26 2024-08-02 Takeda Pharmaceutical Company Limited 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033430B2 (ja) * 1980-05-12 1985-08-02 小野薬品工業株式会社 プロスタグランジン類似化合物
NZ225045A (en) * 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
FR2647015B1 (fr) * 1989-05-17 1994-05-06 Cird Gel aqueux a base d'acide retinoique et son utilisation en medecine humaine et en cosmetique
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
TW200402B (es) * 1990-08-13 1993-02-21 Senju Pharma Co
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
EP0674528A4 (en) * 1992-12-02 1996-06-26 Insite Vision Inc DRUG DELIVERY SYSTEM BASED ON CYCLODEXTRIN AND A POLYMER.
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
SE501482C2 (sv) * 1993-06-24 1995-02-27 Leiras Oy Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
EP0689844A1 (en) * 1994-06-23 1996-01-03 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Complexes of vinpocetine formed with cyclodextrins, process for their preparation and pharmaceutical compositions containing them
AU7637296A (en) * 1995-11-14 1997-06-05 Farmarc Nederland Bv Complex of naproxen and beta-cyclodextrin

Also Published As

Publication number Publication date
US20020150616A1 (en) 2002-10-17
PT998304E (pt) 2004-01-30
HUP0004924A2 (hu) 2001-08-28
JP2002511073A (ja) 2002-04-09
GB9711643D0 (en) 1997-07-30
IL133293A0 (en) 2001-04-30
NO995925D0 (no) 1999-12-03
KR20010005852A (ko) 2001-01-15
CN1258220A (zh) 2000-06-28
EP0998304A1 (en) 2000-05-10
NO995925L (no) 2000-01-11
WO1998055148A1 (en) 1998-12-10
DK0998304T3 (da) 2003-12-01
ZA984849B (en) 1999-12-06
DE69817363D1 (de) 2003-09-25
ATE247489T1 (de) 2003-09-15
ES2206949T3 (es) 2004-05-16
DE69817363T2 (de) 2004-06-24
CA2292506A1 (en) 1998-12-10
AU8108198A (en) 1998-12-21
EP0998304B1 (en) 2003-08-20

Similar Documents

Publication Publication Date Title
AR012927A1 (es) Una composicion farmaceutica, una forma de dosificacion farmaceutica, el uso de dicha composicion para la fabricacion de un medicamento y una forma depresentacion farmaceutica adecuada para la venta comercial
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
SV2002000250A (es) Formula de dosis de droga accionada por hidrogel ref. pc10818ajtb/bb
DE122011100049I1 (de) Stabile pharmazeutische Losungsformulierungen fur unter Druck stehende Inhaliergerate fur die Verabreichung abgemessener Dosen.
KR950007841A (ko) 트라마돌 염을 함유하는 서방성 약물 제제
DE60325354D1 (de) Topisch anwendbare pharmazeutische zubereitung
AR006678A1 (es) Derivados de macrolidas triciclicas, una composicion farmaceutica que los contiene, uso de los mismos para preparar medicamentos y procedimientopara su preparacion
AR011728A1 (es) FORMULACIoN FARMACÉUTICA DE GRÁNUKOS ENTÉRICOS DE FLUOXETINA Y SU USO PARA PREPARAR UN MEDICAMENTO.
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
ATE341309T1 (de) Pulmonale arzneistoffverabreichung
DK0998916T3 (da) Lægemidler til administration til slimhinden
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
AR029403A1 (es) Derivados n-sustituidos de carbamoiloxialquil-azolio,un proceso para su fabricacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento
AR011133A1 (es) MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA.
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
BR0014826A (pt) Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm
AR013864A1 (es) COMPOSICIONES FARMACEUTICAS PARA LA PREVENCIoN PRIMARIA DEL CANCER DE PECHO EN UNA MUJER POST MENOPÁUSICA Y SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO
AR026072A1 (es) Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
UY27644A1 (es) Sistema de suministro osmótico
PE20030830A1 (es) Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea
AR017664A1 (es) Formulaciones farmaceuticas de liberacion sostenida que contienen inhibidores de la alfa-glucosidasa y su uso para la manufactura de un medicamento